Cayman Chemical / Cayman Pharma s.r.o.
Ann Arbor, MI (Cayman Chemical) / Neratovice, Czech Republic (Cayman Pharma)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Cayman Chemical / Cayman Pharma s.r.o.
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Ann Arbor, MI (Cayman Chemical) / Neratovice, Czech Republic (Cayman Pharma)
- Modalities
- Prostaglandin API, Small Molecule API, Psychedelic APIs, Cationic Lipids, Biochemicals
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesProstaglandin API, Small Molecule API, Psychedelic APIs, Cationic Lipids, Biochemicals
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (5 modalities)
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: